Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.8M Buy
573,220
+110,220
+24% +$2.43M 0.13% 270
2026
Q1
$6.77M Buy
463,000
+193,000
+71% +$2.83M 0.07% 417
2025
Q4
$3.41M Buy
+270,000
New +$3.98M 0.03% 521
2025
Q1
Sell
-53,000
Closed -$1.26M 855
2024
Q4
$1.26M Buy
53,000
+13,000
+33% +$363K 0.01% 694
2024
Q3
$1.12M Sell
40,000
-4,000
-9% -$113K 0.01% 715
2024
Q2
$1.15M Buy
44,000
+19,000
+76% +$395K 0.01% 699
2024
Q1
$547K Sell
25,000
-5,979
-19% -$128K ﹤0.01% 786
2023
Q4
$721K Sell
30,979
-30,433
-50% -$612K 0.01% 762
2023
Q3
$1.21M Buy
61,412
+28,994
+89% +$571K 0.01% 717
2023
Q2
$735K Buy
+32,418
New +$653K 0.01% 788

Other funds holding RXO

Royce & Associates's RXO Position: Q2 2026 in Review

Royce & Associates increased its RXO (RXO) stake by 24% in Q2 2026, buying an estimated $2.43M and bringing the position to 573,220 shares worth $15.8M. The position accounts for 0.13% of the portfolio, ranked #270.

Royce & Associates first reported a position in RXO in Q2 2023 and has held it in 10 quarters since. 304 funds tracked by Wall St. Rank hold RXO as of Q2 2026.

  • Royce & Associates held 573,220 shares of RXO worth $15.8M as of Q2 2026.
  • Royce & Associates bought 110,220 RXO shares in Q2 2026, an estimated $2.43M.
  • RXO made up 0.13% of Royce & Associates's portfolio in Q2 2026, its #270 holding.
  • Royce & Associates first reported a position in RXO in Q2 2023 and has held it in 10 quarters since.
  • 304 funds tracked by Wall St. Rank held RXO as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.